Rotavirus vaccination effectiveness: A case–case study in the EDICS project, Castellón (Spain)

Bellido-Blasco, Juan B.; Sabater-Vidal, Susana; Salvador-Ribera, Ma del Mar; Arnedo-Pena, Alberto; Tirado-Balaguer, Ma Dolores; Meseguer-Ferrer, Noemí; Silvestre-Silvestre, E.; Romeu-García, Ma Àngels; Herrero-Carot, Concha; Moreno-Muñoz, Ma Rosario

doi:10.1016/j.vaccine.2012.10.049

Cited by 18 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This question cannot be readily answered in murine models of giardiasis because no meaningful clinical disease develops in these preclinical models. In any case, complete protection may not be necessary to achieve significant public health benefits for a vaccine, as documented for vaccines against rotavirus and other enteric infectious agents (64,65).…”

Section: Discussionmentioning

confidence: 99%

Identification of Conserved Candidate Vaccine Antigens in the Surface Proteome of Giardia lamblia

et al. 2019

View full text Add to dashboard Cite

Giardia lamblia, one of the most common protozoal infections of the human intestine, is an important worldwide cause of diarrheal disease, malabsorption, malnutrition, delayed cognitive development in children, and protracted postinfectious syndromes. Despite its medical importance, no human vaccine is available against giardiasis. A crude veterinary vaccine has been developed, and experimental vaccines based on expression of multiple variant-specific surface proteins have been reported, but poorly defined vaccine components and excessive antigen variability are problematic for pharmaceutical vaccine production. To expand the repertoire of antigen candidates for vaccines, we reasoned that surface proteins may provide an enriched source of such antigens since key host effectors, such as secretory IgA, can directly bind to such antigens in the intestinal lumen and interfere with epithelial attachment. Here, we have applied a proteomics approach to identify 23 novel surface antigens of G. lamblia that show Ͼ90% amino acid sequence identity between the two humanpathogenic genetic assemblages (A and B) of the parasite. Surface localization of a representative subset of these proteins was confirmed by immunostaining. Four selected proteins, uridine phosphorylase-like protein-1, protein 21.1 (GL50803_27925), ␣1-giardin, and ␣11-giardin, were subsequently produced in recombinant form and shown to be immunogenic in mice and G. lamblia-infected humans and confer protection against G. lamblia infection upon intranasal immunization in rodent models of giardiasis. These results demonstrate that identification of conserved surface antigens provides a powerful approach for overcoming a key rate-limiting step in the design and construction of an effective vaccine against giardiasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of Conserved Candidate Vaccine Antigens in the Surface Proteome of Giardia lamblia

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Our report represents the first case-control study matched by gender and age that analyses risk factors for rotavirus infection conducted in Spain, and contributes to assessing rotavirus vaccine effectiveness in Europe. Recently, several casecontrol studies carried out in Europe have been published, but few of them were matched by sex, age and timeframe of admission [18][19][20][21]. In our study, this matching has improved the comparability among the three groups with regard to risk factors for rotavirus disease.…”

Section: Discussionmentioning

confidence: 84%

“…Since Control group B did not have AGE misclassification of cases and these controls was unlikely. Other non-matched case-control studies that have investigated rotavirus vaccine effectiveness in Spain have been published recently [19][20][21]. In those studies, controls were older, less frequently hospitalized, and were seen in a different timeframe, making it necessary to use adjusted multiple logistic regression analyses.…”

Section: Discussionmentioning

confidence: 99%

A Matched Case-Control Study Measuring the Effectiveness of the Rotavirus Vaccines to Prevent Gastroenteritis Hospitalizations

Giménez-Sánchez¹

2015

J Vaccines Vaccin

View full text Add to dashboard Cite

Rotavirus has been identified as an important cause of diarrhea hospitalizations. Two oral live rotavirus vaccines have been licensed in Europe since 2006 and have been available in the Spanish market since then. The main objective of this study was to estimate the effectiveness of the rotavirus vaccination in the prevention of admissions caused by rotavirus infections using a matched case-control study in a hospital setting. Patients and methods: Prospective, hospital based, matched case-control study including patients between aged between 2 months and 5 years, hospitalized during 2008-2010 with a diagnosis of Rotavirus Acute Gastroenteritis (RV+AGE) matched against two patients diagnosed as Rotavirus negative Acute Gastroenteritis (Control group A) and five patients hospitalized with non-gastrointestinal conditions (Control group B) (i.e. in the ratio 1:2:5). Results: 466 patients were included: 57 cases of RV+AGE, 104 patients in Control group A and 305 in Control group B. No differences were found among the 3 groups when comparing demographic data. Vaccine effectiveness was estimated as 86% (95% CI 59-95) compared to group A and 88% (95% CI 68-95) compared to group B. Prior rotavirus vaccination was more frequent in mild cases than in those with moderate-severe symptoms and the length of admission was shorter in vaccine recipients (1.7 ± 0.8 days) compared to those non-vaccinated (3.2 ± 1.4 days) (p<0.001; 95% CI: 1.3-1.7). Conclusions: Our study found the rotavirus vaccines to be highly effective in preventing rotavirus-related hospitalizations and to reduce the severity of the rotavirus disease.

show abstract

“…Систематический обзор наблюдательных исследова-ний эффективности вакцинации против РВИ в Европе [6] обнаружил 9 исследований, в которых анализировалась эффективность вакцинации против РВИ (с примене-нием как 5-валентной, так и одновалентной вакцины) в отношении частоты госпитализации вакцинированных детей по поводу РВИ [7][8][9][10][11][12][13][14][15]. В соответствии с их резуль-татами, средняя величина эффекта при полном курсе вакцинации варьирует в пределах 80-98,3% [6].…”

Section: One Of the Main Causes Of The Incidence Of Intestinal Infectunclassified

“…Влияние вакцинации на частоту амбулаторных слу-чаев заболевания РВИ в Европе оценивалось в 4 иссле-дованиях [10,11,13,14]. При этом было выявлено, что при полном курсе вакцинации эффективность варьирует в пределах 68-75% [6].…”

Section: One Of the Main Causes Of The Incidence Of Intestinal Infectunclassified

Evaluation of the Cost-Effectiveness of Vaccination of Children with 5-valent Vaccine against Rotavirus Infection in the Russian Federation

Рудакова¹,

Харит²,

Podkolzin³

et al. 2017

Pediatr. farmakol.

View full text Add to dashboard Cite

Rotavirus vaccination effectiveness: A case–case study in the EDICS project, Castellón (Spain)

Cited by 18 publications

References 25 publications

Identification of Conserved Candidate Vaccine Antigens in the Surface Proteome of Giardia lamblia

Identification of Conserved Candidate Vaccine Antigens in the Surface Proteome of Giardia lamblia

A Matched Case-Control Study Measuring the Effectiveness of the Rotavirus Vaccines to Prevent Gastroenteritis Hospitalizations

Evaluation of the Cost-Effectiveness of Vaccination of Children with 5-valent Vaccine against Rotavirus Infection in the Russian Federation

Contact Info

Product

Resources

About